Azole antifungal agents

Clinical Infectious Diseases

Volumn 14, Issue , 1992, Pages S161-S169

  Bodey, Gerald P ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 CHLOROPHENYL) 2 (4 CHLOROPHENYL) 1 (1H 1,2,4 TRIAZOL 1 YL) 3 BUTEN 2 OL; ALPHA (4 CHLOROPHENYL) ALPHA (1 CYCLOPROPYL 1 METHYLETHYL) 1H 1,2,4 TRIAZOLE 1 ETHANOL; AMPHOTERICIN B; BUTOCONAZOLE; CLOTRIMAZOLE; ECONAZOLE; ELECTRAZOLE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LANOCONAZOLE; MICONAZOLE; OXICONAZOLE; SAPERCONAZOLE; TERCONAZOLE; TIOCONAZOLE;

ANEMIA; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG INTERACTION; DRUG MECHANISM; DRUG STRUCTURE; FEVER; HEADACHE; HUMAN; HYPOTHYROIDISM; LIVER TOXICITY; MYCOSIS; NAUSEA; PHARMACOKINETICS; PRIORITY JOURNAL; VOMITING;

ANIMAL; ANTIFUNGAL AGENTS; AZOLES; FLUCONAZOLE; HUMAN; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; MYCOSES;

EID: 85047697649     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/clinids/14.Supplement_1.S161     Document Type: Article

References (39)

1. Burgess MA, Bodey GP. Clotrimazole (Bay b 5097): in vitro and clinical pharmacological studies. Antimicrob Agents Chemother 1972;2:423-6.
2. Van den Bossche H, Willemsens G, Cools W, Lauwers WFJ, Le Jeune L. Biochemical effects of miconazole on fungi. II. Inhibition of ergos-terol biosynthesis in Candia albicans. Chem Biol Interact 1978;21:59-78.
3. Van Cutsem J. The in vitro antifungal spectrum of itraconazole. Mycoses 1989;32(suppl 1):7-13.
4. Hoeprich PD, Finn PD. Obfuscation of the activity of antifungal anti-microbics by culture media. J Infect Dis 1972;126:353-61.
5. Kobayashi GS, Spitzer ED. Testing of organisms for susceptibility to triazoles: is it justified? Eur J Clin Microbiol Infect Dis 1989;8: 387-9.
6. Hector RF, Yee E. Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis. Antimicrob Agents Chemother 1990; 34:448-54.
7. Pappagianis D, Zimmer BL, Theodoropoulos G, Plempel M, Hector RF. Therapeutic effect of the triazole Bay R 3783 in mouse models of coccidioidomycosis, blastomycosis, and histoplasmosis. Antimicrob Agents Chemother 1990;34:1132-8.
8. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988;14:13-34.
9. Hann IM, Prentice HG, Corringham R, et al. Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients. Lancet 1982;1:826-9.
10. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990; 12(suppl 3):S318-26.
11. Heykants J, Van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989;32(suppl 1):67-87.
12. Cauwenbergh G. Safety aspects of ketoconazole, the most commonly used systemic antifungal. Mycoses 1989;32(suppl 2):59-63.
13. Weber MM, Luppa P, Engelhardt D. Inhibition of human adrenal androgen secretion by ketoconazole. Klin Wochenschr 1989;67:707-12.
14. Sharkey PK, Rinaldi MG, Lerner CJ, Fetchick RJ, Dunn FJ, Graybill JR. High dose itraconazole in the treatment of severe mycoses, (abstract no 575). In: Program and abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1988:210.
15. Kraemer FB, Pont A. Inhibition of cholesterol synthesis by ketoconazole. Am J Med 1986;80:616-22.
16. Vuddhakul V, Mai GT, McCormick JG, Seow WI, Thong YH. Suppression of neutrophil and lymphoproliferative responses in vitro by itraconazole but not fluconazole. Int J Immunopharmacol 1990;12:639-45.
17. Schentag JJ. Drug interaction studies and safety profile of fluconazole. Hospital Formulary 1991;26:16-20.
18. Kramer MR, Marshall SE, Denning DW, et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med 1990; 113:327-9.
19. Heel RC, Brogden RN, Pakes GE, Speight JM, Avery GS. Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections. Drugs 1980;19:7-30.
20. Lambert DR, Siegle RJ, Camisa C. Griseofulvin and ketoconazole in the treatment of dermatophyte infections. Int J Dermatol 1989; 28:300-4.
21. National Institute of Allergy and Infectious Diseases Mycoses Study Group, Birmingham, Alabama and Bethesda, Maryland. Treatment of blastomycosis and histoplasmosis with ketoconazole. Results of a prospective randomized clinical trial. Ann Intern Med 1985; 103:861-72.
22. Fainstein V, Bodey GP, Elting L, Maksymiuk A, Keating M, McCredie KB. Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients. Antimicrob Agents Chemother 1987;31:11-5.
23. Bodey GP. Antimicrobial prophylaxis for infection in neutropenic patients. In: Remington JS, Swartz MN, eds. Current clinical topics in infectious diseases. 9th ed. New York: McGraw-Hill, 1988:1-43.
24. Samonis G, Rolston K, Karl C, Miller P, Bodey GP. Prophylaxis of oropharyngeal candidiasis with fluconazole. Rev Infect Dis 1990; 12(suppl 3):S369-73.
25. DeWit S, Weerts D, Goossens H, Clumeck N. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet 1989;1:746-8.
26. Laine L, Conteas C, Islam MZ, DeBruin M, Multicenter Study Group. A prospective, randomized, double-blind trial of fluconazole vs. ketoconazole for Candida esophagitis: final results. Gastroenterology 1991; 100(5 Pt 2):A591.
27. Brammer KW, Feczko JM. Single-dose oral fluconazole in the treatment of vaginal candidiasis. Ann NY Acad Sci 1988;544:561-3.
28. Ikemoto H. A clinical study of fluconazole for the treatment of deep mycoses. Diagn Microbiol Infect Dis 1989;12(suppl 4):239S-47S.
29. Larsen RA, Leal MAE, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Intern Med 1990; 113:183-7.
30. Dismukes W, Cloud G, Thompson S, et al. Fluconazole versus amphotericin B therapy of acute cryptococcal meningitis (NIAID Mycoses Study Group) (abstract no 1065). In: Program and abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1989:282.
31. Powderly W, Saag M, Coug G, et al. Fluconazole (FLU) versus amphotericin B (AMB) as maintenance therapy for prevention of relapse of AIDS-associated cryptococcal meningitis (CM) (abstract no 1162). In: Programs and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1990:280.
32. Galgiani JN, Catanzaro A, Graybill JR, et al. Fluconazole therapy for coccidioidomycosis (abstract no 574). In: Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1990:181.
33. Bourlond A, Lachapelle JM, Aussems J, et al. Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea corporis and tinea cruris. Int J Dermatol 1989;28:410-2.
34. Bailey EM, Krakovsky DJ, Rybak MJ. The triazole antifungal agents: a review of itraconazole and fluconazole. Pharmacotherapy 1990; 10:146-55.
35. Grant SM, Clissold SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989;37:310-44.
36. Tucker RM, Denning DW, Arathoon EG, Rinaldi MG, Arathoon EG, Stevens DA. Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. J Am Acad Dermatol 1990;23:593-601.
37. Tucker RM, Denning DW, Dupont B, Stevens DA. Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med 1990;112:108-12.
38. Denning DW, Tucker RM, Hanson LH, Stevens DA. Treatment of invasive aspergillosis with itraconazole. Am J Med 1989;86:791-800.
39. Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, De-Beule K. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989;32(suppl 1): 103-8.